In contrast, the associations between other glucose-lowering drugs, such as alpha-glucosidase inhibitors, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-4 inhibitors, and cancer risk remain inconclusive, likely influenced by specific medications, dosages, and treatment durations [9]. Here, GCG is linked to cancer.